Our study found that SLC16A1 could serve as a biomarker for the prediction of OS and PFS of urological cancers and identifying cancer subtypes with higher prognostic risk, especially in several cancers of ACC, KIRC and KICH. The gene discussed is SLC16A1; the disease is adrenal cortex carcinoma.